Abstract
Neurofibrillary tangles (NFTs) are one of the pathological hallmarks of Alzheimers disease (AD) and are primarily composed of aggregates of hyperphosphorylated forms of the microtubule associated protein tau. It is likely that an imbalance of kinase and phosphatase activities leads to the abnormal phosphorylation of tau and subsequent aggregation. The wide ranging therapeutic approaches that are being developed include to inhibit tau kinases, to enhance phosphatase activity, to promote microtubule stability, and to reduce tau aggregate formation and/or enhance their clearance with small molecule drugs or by immunotherapeutic means. Most of these promising approaches are still in preclinical development whilst some have progressed to Phase II clinical trials. By pursuing these lines of study, a viable therapy for AD and related tauopathies may be obtained.
Keywords: Tau, therapy, kinases, phosphatase, aggregation, immunotherapy, neurodegenerative disorder, SORL1, PHF, Alz 50, immunoblotting
Current Alzheimer Research
Title: Tau as a Therapeutic Target for Alzheimers Disease
Volume: 8 Issue: 6
Author(s): A. Boutajangout, E. M. Sigurdsson and P. K. Krishnamurthy
Affiliation:
Keywords: Tau, therapy, kinases, phosphatase, aggregation, immunotherapy, neurodegenerative disorder, SORL1, PHF, Alz 50, immunoblotting
Abstract: Neurofibrillary tangles (NFTs) are one of the pathological hallmarks of Alzheimers disease (AD) and are primarily composed of aggregates of hyperphosphorylated forms of the microtubule associated protein tau. It is likely that an imbalance of kinase and phosphatase activities leads to the abnormal phosphorylation of tau and subsequent aggregation. The wide ranging therapeutic approaches that are being developed include to inhibit tau kinases, to enhance phosphatase activity, to promote microtubule stability, and to reduce tau aggregate formation and/or enhance their clearance with small molecule drugs or by immunotherapeutic means. Most of these promising approaches are still in preclinical development whilst some have progressed to Phase II clinical trials. By pursuing these lines of study, a viable therapy for AD and related tauopathies may be obtained.
Export Options
About this article
Cite this article as:
Boutajangout A., M. Sigurdsson E. and K. Krishnamurthy P., Tau as a Therapeutic Target for Alzheimers Disease, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717195
DOI https://dx.doi.org/10.2174/156720511796717195 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Applications of Gene Therapy to the Treatment of Chronic Pain
Current Gene Therapy Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Pathways by Which Aβ Facilitates Tau Pathology
Current Alzheimer Research The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy Varicella-Zoster Virus Infections During Pregnancy: Epidemiology, Clinical Symptoms, Diagnosis, Prevention and Therapy
Current Pediatric Reviews HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Gene Therapy to Improve Pancreatic Islet Transplantation for Type 1 Diabetes Mellitus
Current Diabetes Reviews Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) Anti-NMDA Receptor Encephalitis, Vaccination and Virus
Current Pharmaceutical Design Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Mathematical Models for the Management of Helminth Parasites: From Biological Processes to the Evolution of Anthelmintic Resistance
Anti-Infective Agents in Medicinal Chemistry Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design